Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Nov 10, 2007 12:43pm
322 Views
Post# 13788224

RE: Pfizer...........

RE: Pfizer........... "Very well could be Pfizer.....We do know ther are in discussions with nuemrous parties for GLP1-INT." Yes they are , Dr. Cruz had mentioned that as soon as the Results were released showing 6 Months Sustained Efficacy, that numerous parties had suddenly began to knock on the door. However I think that Transition wants to partner the Whole INT(tm) Technology and not just GLP1/TT-223 (the old GLP1-INT.) That would include the Stand Alone therapy TT-223 which BTW the SAD Trial started in September on the 29th andis fully enrolled and dosing. Also included would be E1/TT-223 as well as E1/T-223 For Transplantation (NN never did have that). Also TT-223/DDP4 Inhibitors. Pfizer could be interested in just TT-223 Stand Alone I would think. What a great replacement for 'Exubera' 'eh!! Pfizer wanted into the 'Hyperglycemia Market'and Rapid Acting human Insulin just wasn't the answer. If Dr. Cruz got the right Big Money for it he might let it go......but it would have to be tres large!!! Pending SAD and MAD results in Feb. of course. Because TT-223 is actually the cornerstone to the technology I can see it being worth perhaps 3 or 4 times more than just GLP1/TT-223 or just E1/TT-223 etc. If TT-223 is efficacious as a Stand Alone we'll have the ultimate bargaining chip!! Inhaled Insulin failed for various reasons for Pfizer. Introduced to the market in summer 2006 and announced failure October 2007. Off the market in January 08. It was their only 'Hyperglycemia Drug'........Are they in the market for a patient friendly Hyperglycemic??? Stay Tuned is all I can say at this time....... What do you think??? GPP all.....
Bullboard Posts